Isracann Biosciences Stock Shares Outstanding

Isracann Biosciences fundamentals help investors to digest information that contributes to Isracann Biosciences' financial success or failures. It also enables traders to predict the movement of Isracann Pink Sheet. The fundamental analysis module provides a way to measure Isracann Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Isracann Biosciences pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Isracann Biosciences Company Shares Outstanding Analysis

Isracann Biosciences' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Isracann Biosciences Shares Outstanding

    
  175.99 M  
Most of Isracann Biosciences' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Isracann Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Isracann Biosciences has 175.99 M of shares currently outstending. This is 2.52% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 69.22% higher than that of the company.

Isracann Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Isracann Biosciences' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Isracann Biosciences could also be used in its relative valuation, which is a method of valuing Isracann Biosciences by comparing valuation metrics of similar companies.
Isracann Biosciences is currently under evaluation in shares outstanding category among its peers.

Isracann Fundamentals

About Isracann Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Isracann Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Isracann Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Isracann Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Isracann Pink Sheet

Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.